Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website


Werte in diesem Artikel
Aktien

91.50 EUR -0.50 EUR -0.54 %

Financial release accessible online

BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted to its Investor Relations website the earnings release and certain supplemental tables that will be referenced during the call and include additional information supporting fiscal 2026 total Company and Hospital reported and organic revenue growth guidance.

Direct link to 4Q FY25 Earnings Release:
https://haemonetics.gcs-web.com/static-files/89295437-34ea-473c-ae6e-409a07328239

Direct link to Hospital Reported and Organic Revenue Growth Guidance Supplemental Tables:
https://haemonetics.gcs-web.com/static-files/320de990-2769-4b30-beca-eff1ca68bad1 

A replay of the conference call and webcast will be available for one year beginning on May 8, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                                     


Olga Guyette, Vice President-Investor Relations & Treasury         

David Trenk, Manager-Investor Relations

(781) 356-9763                                                                           

(203) 733-4987

olga.guyette@haemonetics.com                                     

david.trenk@haemonetics.com                                                                               

 

Media Contact:         
Josh Gitelson, Sr. Director-Global Communications      
(781) 356-9776
josh.gitelson@haemonetics.com


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-4th-quarter-and-fiscal-year-2025-earnings-release-available-on-investor-relations-website-302449085.html

SOURCE Haemonetics Corporation

Aktuelle Haemonetics Aktie News

Werbung

Haemonetics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Haemonetics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
07.08.19 Haemonetics Outperform Barrington Research
08.05.19 Haemonetics Outperform Barrington Research
09.08.18 Haemonetics Outperform Barrington Research
07.02.18 Haemonetics Outperform Barrington Research
08.11.17 Haemonetics Outperform Barrington Research

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.